News coverage about Fluidigm (NASDAQ:FLDM) has been trending somewhat positive on Friday, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Fluidigm earned a news impact score of 0.17 on Accern’s scale. Accern also assigned news coverage about the medical research company an impact score of 46.6628437529702 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Here are some of the media stories that may have effected Accern Sentiment’s analysis:
A number of brokerages recently weighed in on FLDM. BidaskClub cut shares of Fluidigm from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 24th. ValuEngine cut shares of Fluidigm from a “sell” rating to a “strong sell” rating in a research report on Friday, February 2nd. Piper Jaffray reissued a “hold” rating and issued a $6.10 price target on shares of Fluidigm in a research report on Thursday, February 8th. Finally, Zacks Investment Research upgraded shares of Fluidigm from a “hold” rating to a “buy” rating and set a $6.25 price objective on the stock in a research note on Wednesday.
NASDAQ FLDM traded down $0.05 during trading on Friday, reaching $5.74. The company’s stock had a trading volume of 65,728 shares, compared to its average volume of 193,185. The company has a debt-to-equity ratio of 3.38, a quick ratio of 1.95 and a current ratio of 2.40. The firm has a market cap of $224.94 million, a PE ratio of -4.82 and a beta of 3.01. Fluidigm has a twelve month low of $5.55 and a twelve month high of $5.74.
Fluidigm (NASDAQ:FLDM) last posted its quarterly earnings data on Thursday, May 3rd. The medical research company reported ($0.34) EPS for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.07. The company had revenue of $25.25 million for the quarter, compared to analyst estimates of $25.40 million. Fluidigm had a negative net margin of 55.66% and a negative return on equity of 98.85%. research analysts predict that Fluidigm will post -0.9 earnings per share for the current year.
In other Fluidigm news, insider Levin Capital Strategies, L.P. acquired 250,355 shares of the company’s stock in a transaction on Friday, March 2nd. The shares were bought at an average cost of $6.25 per share, for a total transaction of $1,564,718.75. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last 90 days, insiders acquired 538,052 shares of company stock worth $3,251,137. 4.70% of the stock is currently owned by company insiders.
Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents. The company also provides preparatory instruments, such as access array and Juno systems; and analytical instruments comprising Biomark HD system and EP1 system.
Receive News & Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related companies with MarketBeat.com's FREE daily email newsletter.